Association between PCSK9 inhibitor with cause-specific morality amongst cancer survivors

Back

ESC Professional Premium Access

Association between PCSK9 inhibitor with cause-specific morality amongst cancer survivors

Session: Cardio-oncology: treatments and outcomes

Topic: Cardio-Oncology

Speaker: Doctor T. Liu (Tianjin, CN)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Tong Liu

2nd Hospital of Tianjin Medical University, Tianjin (China)

1 follower

9 more presentations in this session

The impact of peptide receptor radionucleotide therapy with Lutetium-177 DOTATATE on cardiac metastases in neuroendocrine tumors

Speaker: Associate Professor C. Ayoub (Scottsdale, US)

The predictive value of coronary artery calcium deposit for cardiovascular events in patients treated with immune checkpoint inhibitor therapy

Speaker: Doctor M. Slieman (Tel Aviv, IL)

Long term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis

Speaker: Doctor J. Wong (Melbourne, AU)

Assessment of right ventricular dysfunction in breast cancer patients undergoing anthracycline and trastuzumab treatment

Speaker: Doctor M. Santa Ana Bayona (Mexico City, MX)

Incidence of acute cardiovascular hospitalizations and association with hemodynamic biomarkers in cancer patients treated with Immune Checkpoint Inhibitor therapy

Speaker: Doctor C. Mann (Vienna, AT)

Access the full session

Cardio-oncology: treatments and outcomes

Speakers: Doctor T. Liu, Associate Professor C. Ayoub, Doctor M. Slieman, Doctor J. Wong, Doctor M. Santa Ana Bayona...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources